Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 wild-type |
| Therapy | p53-SLP vaccine |
| Indication/Tumor Type | ovarian cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | ovarian cancer | no benefit | p53-SLP vaccine | Phase II | Actionable | In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579). | 21328579 19621448 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (19621448) | Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. | Full reference... |
| (21328579) | Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. | Full reference... |